Werewolf Therapeutics Reports Third Quarter 2023 Financial
– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of...
Source: globenewswire.com
Danielj Hicklin News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Danielj Hicklin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Danielj Hicklin Today - Breaking & Trending Today
Werewolf Therapeutics Reports Second Quarter 2023 Financial
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical...
Source: globenewswire.com
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
24.02.2023 - WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the safety, tolerability, and clinical activity of WTX-330 in Patients with Advanced or Metastatic Solid Tumors ... Seite 1
Source: wallstreet-online.de
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors
01.09.2022 - - First clinical candidate of a new class of systemically delivered conditionally activated INDUKINE therapeutics developed by Werewolf - WTX-124 is designed to target delivery of a highly potent, wild-type IL-2 cytokine to the tumor ... Seite 1
Source: wallstreet-online.de
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNa INDUKINE Molecule
Werewolf to receive $15 million upfront payment, with potential for up to $1.26 billion in development, regulatory and sales milestone payments in addition to royalties on future net
Source: finanznachrichten.de